Case Report: Composite Angioimmunoblastic T-Cell Lymphoma and Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder as Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders.

Epstein-Barr virus reactivation angioimmunoblastic T-cell lymphoma (AITL) clonal expansion composite lymphoma methotrexate

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2020
Historique:
received: 03 11 2020
accepted: 07 12 2020
entrez: 11 1 2021
pubmed: 12 1 2021
medline: 12 1 2021
Statut: epublish

Résumé

Immunosuppressants are widely used to treat patients with rheumatoid arthritis (RA), and their adverse effects have been known to cause other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). We report a patient with RA who had been treated with methotrexate (MTX) and tacrolimus (TAC) and who developed whole body lymphadenopathy. We simultaneously confirmed angioimmunoblastic T-cell lymphoma (AITL) through a right cervical lymph node biopsy and Epstein-Barr virus-positive B-cell lymphoproliferative disorder (EBV-positive B-LPD) through a bone marrow examination. After cessation of immunosuppressant therapy, both LPDs completely disappeared. Patients with AITL are occasionally reported to develop B-cell lymphoma through reactivation of the EBV, which leads to clonal expansion in the microenvironment. Immunohistochemistry results revealed that both LPD components were positive for EBV-encoded RNA. Moreover, in this patient, the plasma EBV DNA level was found to be high; therefore, EBV infection was a probable etiology. Synchronous coexistence of AITL and B-LPD as an OIIA-LPD has rarely been reported. This case report is the first to discuss the disappearance of both LPDs on withdrawal of immunosuppressants only. AITL occasionally accompany B-LPD; however, this composite lymphoma comprised AITL and B-LPD, and OIIA-LPDs should not be overlooked.

Identifiants

pubmed: 33425968
doi: 10.3389/fmed.2020.625442
pmc: PMC7785868
doi:

Types de publication

Case Reports

Langues

eng

Pagination

625442

Informations de copyright

Copyright © 2020 Kakiuchi, Yakushijin, Takagi, Rikitake, Akiyama, Matsuba, Hayashi, Kajimoto and Iwata.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Intern Med. 2019 Nov 1;58(21):3167-3171
pubmed: 31292392
Blood. 2002 Jan 15;99(2):627-33
pubmed: 11781247
Mod Rheumatol. 2010 Oct;20(5):500-5
pubmed: 20437072
Pathol Int. 2012 Oct;62(10):690-8
pubmed: 23005596
Am J Hematol. 2007 Dec;82(12):1106-9
pubmed: 17654684
Mod Pathol. 2019 Jul;32(8):1135-1146
pubmed: 30952973
J Rheumatol. 2007 Feb;34(2):322-31
pubmed: 17117491
Am J Blood Res. 2016 May 18;6(1):1-5
pubmed: 27335685
Mod Rheumatol. 2016;26(2):271-5
pubmed: 24386983
Int J Dev Biol. 2005;49(2-3):285-92
pubmed: 15906243
J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702
pubmed: 15547182
Appl Immunohistochem Mol Morphol. 2009 Mar;17(2):102-7
pubmed: 18838918
Cancer Med. 2018 Nov;7(11):5843-5858
pubmed: 30311404
J Exp Med. 2001 Oct 1;194(7):927-40
pubmed: 11581315
Virchows Arch. 2013 Apr;462(4):399-407
pubmed: 23494713
Cancer Res. 2007 Nov 15;67(22):10703-10
pubmed: 18006812
Int J Clin Exp Pathol. 2008 Jan 01;1(3):276-84
pubmed: 18784810
JAAD Case Rep. 2016 Aug 27;2(4):354-6
pubmed: 27626055
Blood. 2002 Jun 1;99(11):3909-15
pubmed: 12010788
J Rheumatol. 2014 Feb;41(2):293-9
pubmed: 24334644
Int J Hematol. 2010 Sep;92(2):364-8
pubmed: 20665252
Pathol Res Pract. 2006;202(9):679-85
pubmed: 16859835
Eur J Dermatol. 2015 Jul-Aug;25(4):361-2
pubmed: 26105783
Intern Med. 2018 Jul 15;57(14):2071-2075
pubmed: 29491299
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
Pathol Res Pract. 2010 Jan 15;206(1):9-13
pubmed: 19628340
Br J Haematol. 2007 Sep;138(6):733-9
pubmed: 17672882
Arch Pathol Lab Med. 2000 Sep;124(9):1376-8
pubmed: 10975943
Eur J Haematol. 2013 Jul;91(1):20-8
pubmed: 23560463

Auteurs

Seiji Kakiuchi (S)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.
Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan.

Kimikazu Yakushijin (K)

Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan.

Ikumi Takagi (I)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.

Junpei Rikitake (J)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.
Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, Kobe, Japan.

Hiroaki Akiyama (H)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.

Hiroyuki Matsuba (H)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.

Yoshitake Hayashi (Y)

Division of Molecular Medicine & Medical Genetics, Department of Pathology, Kobe Graduate School of Medicine, Kobe, Japan.

Kazuyoshi Kajimoto (K)

Department of Pathology, Hyogo Cancer Center, Akashi, Japan.

Nobuko Iwata (N)

Department of Hematology, Yodogawa Christian Hospital, Osaka, Japan.

Classifications MeSH